Scientists have spent 30 years finalising the Lecanemab treatment which can delay the decline in memory associated with Alzheimer's disease.

Following further testing, the drug company will apply for licencing in the US and could be fully accessible within "two to three years".

Read more here: [ Ссылка ]

#skynews #alzheimer #medicine

SUBSCRIBE to our YouTube channel for more videos: [ Ссылка ]

Follow us on Twitter: [ Ссылка ]
Like us on Facebook: [ Ссылка ]
Follow us on Instagram: [ Ссылка ]
Follow us on TikTok: [ Ссылка ]

For more content go to [ Ссылка ] and download our apps:
Apple: [ Ссылка ]
Android [ Ссылка ]

Sky News videos are now available in Spanish here/Los video de Sky News están disponibles en español aquí [ Ссылка ]
Sky News videos are also available in German here/Hier können Sie außerdem Sky News-Videos auf Deutsch finden: [ Ссылка ]

To enquire about licensing Sky News content, you can find more information here: [ Ссылка ]

свернуть